01/25/23 8:00 AMNasdaq : ELOX clinical triallow floatEloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport SyndromeEloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the firstRHEA-AIneutral
12/01/22 8:45 AMNasdaq : ELOX low floatEloxx Pharmaceuticals Announces Reverse Stock Split EffectiveEloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced thatRHEA-AIneutral
11/10/22 5:15 PMNasdaq : ELOX low floatEloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business UpdateStarted proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations; topline results expected in the first half of 2023 On track to submit IND application for ZKN-013 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB)RHEA-AIneutral
11/01/22 4:30 PMNasdaq : ELOX clinical triallow floatEloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport SyndromeEloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the opening of clinical trial sites for its Phase 2RHEA-AIneutral
09/14/22 4:05 PMNasdaq : ELOX clinical triallow floatEloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) PatientsCombination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity for ELX-02 observed; efficacy signal potentiallyRHEA-AIneutral
08/15/22 8:00 AMNasdaq : ELOX low floatEloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business UpdateTopline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected by the end of the third quarter of 2022 On track to initiate a proof-of-concept clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations in theRHEA-AIneutral
07/05/22 8:00 AMNasdaq : ELOX managementlow floatEloxx Pharmaceuticals Announces Changes to Board of DirectorsLindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi Veinrib, Ran Nussbaum, Dr. Zafrira Avnur, Dr. Rajesh Parekh and Dr. Jasbir Seehra step down from the Eloxx board WATERTOWN, Mass., July 05, 2022RHEA-AIneutral
05/10/22 8:00 AMNasdaq : ELOX low floatEloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business UpdateCystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected at the end of the first half of 2022 Expanded development of ELX-02RHEA-AIneutral
03/31/22 7:00 AMNasdaq : ELOX low floatEloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business UpdateExpect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program New developmentRHEA-AIpositive
03/30/22 4:15 PMNasdaq : ELOX low floatEloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport SyndromeStrong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical studies and is preferentially transported to kidney Initiation of proof-of-concept clinical trial expected in second half of 2022; topline resultsRHEA-AIneutral